A global leader in molecular cancers diagnostics.

In 2009 November, Palmetto GBA, California’s Part B Medicare administrator, set up coding guidelines for MammaPrint, allowing health care providers from over the United States to submit claims for the test. MammaPrint is the first and only FDA-cleared breast tumor recurrence test available and provides been reimbursed by payors since 2008. ‘Humana is normally focused on advancing excellence in health care delivery with respect to its members. This commitment to quality treatment and patient basic safety has led Humana to include MammaPrint in its medical advantage management plan,’ said Bernhard Sixt, Chief Executive Officer of Agendia.Related StoriesCrucial switch in single DNA bottom predisposes children to aggressive form of cancerOvarian cancer individuals with a brief history of oral contraceptive use possess better outcomesNew RNA check of blood platelets may be used to detect location of cancer While increasing living standards in the coming decades in lower-HDI countries can lead to a lower in the burden of some infection-related cancers, the authors warn that, regardless of future developments, there may be a surge in the types of malignancy which currently affect generally higher-HDI countries.